Top Institutional Investors

GREAT POINT PARTNERS LLC — 13F Holdings & Portfolio

CIK 1281446 · latest 13F-HR filed 2026-08-14

Backtest portfolio

GREAT POINT PARTNERS LLC manages $529.1M in 13F-reported U.S. long-equity assets across 42 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are ABVX (10.07%), VOR (5.91%), ABVX (5.15%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 11 new positions and exited 13; 14 existing positions rose in reported value and 9 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$529.1M

Long-equity book

Holdings
42

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+11 / −13 / ↑14 / ↓9

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26
VOR7.4% · -3%ABVX6.4% · newVERA6.1% · +201%ZURA5.9% · 0%ALMS5.7% · 0%SLGL4.8% · 0%DFTX4.7% · newANNX4.7% · +40%ORKA4.1% · 0%MLTX3.9% · +71%SGMT3.7% · newCTNM3.6% · +15%IMMX3.1% · +265%CLYM3.1% · -25%AMLX3.0% · -60%NKTR2.9% · -45%NGNE2.6% · -30%LBRX2.4% · +6%IRD1.9% · +507%EPRX1.9% · 0%DRUG1.8% · -50%IFRX1.6% · newRLMD1.4% · 0%JATT1.3% · newCGEM1.3% · 0%ALT1.2% · newAMAN1.2% · newRZLT1.2% · 0%SLN1.2% · -56%PALI1.1% · -33%EVMN1.0% · 0%SCYX0.9% · -88%ELVN0.8% · newHUMA0.7% · 0%RNTX0.6% · newDBVT0.6% · newPMN0.3% · -77%

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 53.6%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Mar 31, 2026.

Assets Under Management
$1.78B
Discretionary
$1.78B
Employees
28
Accounts
17
Address
165 MASON STREET
3RD FLOOR
GREENWICH, CT 06830
Phone
(203) 971-3300
Website
Name Title / Status Ownership Type
Felsenthal, Adam, Brian ControlGENERAL COUNSEL AND CHIEF COMPLIANCE OFFICER
since Dec 2023
Less than 5%Individual
JAY, JEFFREY, ROBERT ControlELECTED MANAGER, MEMBER AND MANAGING DIRECTOR
since Jan 2003
50–75%Individual
PANZIER, RONALD, MARC ControlCHIEF OPERATING OFFICER AND CHIEF FINANCIAL OFFICER
since Jul 2010
Less than 5%Individual
THE JAY FAMILY SPRAY TRUSTASSOCIATED NON-MANAGING MEMBER
since Oct 2003
25–50%Domestic Entity
PENN, KEVIN
Indirect owner via THE JAY FAMILY SPRAY TRUST
TRUSTEE
since Oct 2003
General partner, trustee or managerIndividual
Ownership & leadership changes · 8 filings with changes since Feb 14, 2012

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Oct 14, 2024 filing
  • No longer listedYEHUDAI, ORTAV, Daniel · MEMBER, MANAGING DIRECTOR · 5–10% · control person · listed since Jun 2015
Mar 28, 2024 filing
  • No longer listedKROIN, DAVID, ERIC · MEMBER · 10–25% · listed since Jan 2003
  • AddedFelsenthal, Adam, Brian · GENERAL COUNSEL AND CHIEF COMPLIANCE OFFICER · Less than 5% · control person
  • ChangedPANZIER, RONALD, MARC · title CHIEF COMPLIANCE OFFICER AND CHIEF FINANCIAL OFFICER → CHIEF OPERATING OFFICER AND CHIEF FINANCIAL OFFICER
Mar 31, 2023 filing
  • No longer listedDOLDER, ADAM, BILLS · MEMBER, MANAGING DIRECTOR · 5–10% · control person · listed since Sep 2012
  • ChangedJAY, JEFFREY, ROBERT · ownership 25–50% → 50–75%
  • ChangedTHE JAY FAMILY SPRAY TRUST · ownership 10–25% → 25–50%
Mar 31, 2022 filing
  • ChangedDOLDER, ADAM, BILLS · title MANAGING DIRECTOR → MEMBER, MANAGING DIRECTOR
  • ChangedKROIN, DAVID, ERIC · no longer a control person
  • ChangedYEHUDAI, ORTAV, Daniel · title MANAGING DIRECTOR → MEMBER, MANAGING DIRECTOR
Oct 23, 2020 filing
  • ChangedKROIN, DAVID, ERIC · title ELECTED MANAGER, MEMBER AND MANAGING DIRECTOR → MEMBER
Jul 14, 2015 filing
  • AddedYEHUDAI, ORTAV, Daniel · MANAGING DIRECTOR · 5–10% · control person
  • ChangedDOLDER, ADAM, BILLS · ownership 10–25% → 5–10%
  • ChangedKROIN, DAVID, ERIC · ownership 25–50% → 10–25%
Mar 30, 2015 filing
  • AddedPENN, KEVIN · TRUSTEE · General partner, trustee or manager · indirect via THE JAY FAMILY SPRAY TRUST
  • AddedTHE JAY FAMILY SPRAY TRUST · ASSOCIATED NON-MANAGING MEMBER · 10–25%
  • ChangedDOLDER, ADAM, BILLS · ownership 5–10% → 10–25%
  • ChangedJAY, JEFFREY, ROBERT · ownership 50–75% → 25–50%
Mar 28, 2013 filing
  • AddedDOLDER, ADAM, BILLS · MANAGING DIRECTOR · 5–10% · control person
Feb 14, 2012 filing (earliest on record)
  • ListedJAY, JEFFREY, ROBERT · ELECTED MANAGER, MEMBER AND MANAGING DIRECTOR · 50–75% · control person
  • ListedKROIN, DAVID, ERIC · ELECTED MANAGER, MEMBER AND MANAGING DIRECTOR · 25–50% · control person
  • ListedPANZIER, RONALD, MARC · CHIEF COMPLIANCE OFFICER AND CHIEF FINANCIAL OFFICER · Less than 5% · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

GREAT POINT PARTNERS LLC Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 ABIVAX SA Call ABVX 00370M103 $53.3M 10.07% 400,000 SH
2 VOR BIOPHARMA INC VOR 929033207 $31.3M 5.91% 1,700,000 SH
3 ABIVAX SA ABVX 00370M103 $27.2M 5.15% 204,314 SH
4 IMMUNITYBIO INC Put IBRX 45256X103 $26.3M 4.97% 3,000,800 SH
5 VERA THERAPEUTICS INC VERA 92337R101 $25.8M 4.87% 600,836 SH
6 ZURA BIO LTD ZURA G9TY5A101 $24.9M 4.70% 4,215,930 SH
7 ALUMIS INC ALMS 022307102 $24.1M 4.55% 856,061 SH
8 SOL-GEL TECHNOLOGIES LTD SLGL M8694L137 $20.3M 3.84% 274,363 SH
9 ULTRAGENYX PHARMACEUTICAL IN Put RARE 90400D108 $20.0M 3.79% 600,000 SH
10 DEFINIUM THERAPEUTICS INC DFTX 24477V105 $20.0M 3.78% 425,000 SH
11 ANNEXON INC ANNX 03589W102 $20.0M 3.78% 3,500,000 SH
12 ORUKA THERAPEUTICS INC ORKA 687604108 $17.4M 3.30% 183,330 SH
13 MOONLAKE IMMUNOTHERAPEUTICS MLTX 61559X104 $16.7M 3.15% 855,813 SH
14 SAGIMET BIOSCIENCES INC SGMT 786700104 $15.7M 2.97% 2,029,933 SH
15 CONTINEUM THERAPEUTICS INC CTNM 21217B100 $15.1M 2.85% 921,481 SH
16 IMMIX BIOPHARMA INC IMMX 45258H106 $13.2M 2.49% 1,277,642 SH
17 CLIMB BIO INC CLYM 28658R106 $13.0M 2.46% 1,000,000 SH
18 AMYLYX PHARMACEUTICALS INC AMLX 03237H101 $12.6M 2.38% 700,000 SH
19 NEKTAR THERAPEUTICS NKTR 640268306 $12.2M 2.31% 175,000 SH
20 NEUROGENE INC NGNE 64135M105 $11.1M 2.09% 352,180 SH
21 LB PHARMACEUTICALS INC LBRX 50180M108 $10.3M 1.95% 317,221 SH
22 OPUS GENETICS INC IRD 67577R102 $8.1M 1.53% 1,970,187 SH
23 EUPRAXIA PHARMACEUTICALS INC EPRX 29842P105 $7.9M 1.50% 1,200,000 SH
24 BRIGHT MINDS BIOSCIENCES INC DRUG 10919W405 $7.7M 1.45% 109,603 SH
25 INFLARX NV IFRX N44821101 $6.8M 1.29% 3,046,557 SH
26 RELMADA THERAPEUTICS INC RLMD 75955J402 $5.8M 1.10% 842,106 SH
27 JATT II ACQUISITION CORP JATT G50765109 $5.7M 1.07% 500,000 SH
28 CULLINAN THERAPEUTICS INC CGEM 230031106 $5.5M 1.03% 300,000 SH
29 ALTIMMUNE INC ALT 02155H200 $5.3M 1.00% 1,741,232 SH
30 AMANAT ACQUISITION CORP AMAN G0375M101 $5.1M 0.96% 500,000 SH
31 REZOLUTE INC RZLT 76200L309 $4.9M 0.94% 951,809 SH
32 SILENCE THERAPEUTICS PLC SLN 82686Q101 $4.9M 0.93% 450,000 SH
33 PALISADE BIO INC PALI 696389402 $4.8M 0.90% 2,284,819 SH
34 EVOMMUNE INC EVMN 30054Y107 $4.3M 0.82% 325,000 SH
35 SCYNEXIS INC SCYX 811292309 $3.8M 0.73% 944,292 SH
36 GALECTIN THERAPEUTICS INC Call GALT 363225202 $3.7M 0.70% 800,000 SH
37 ENLIVEN THERAPEUTICS INC ELVN 29337E102 $3.6M 0.67% 70,000 SH
38 HUMACYTE INC HUMA 44486Q103 $2.9M 0.55% 3,750,000 SH
39 REIN THERAPEUTICS INC RNTX 00887A204 $2.7M 0.51% 2,575,000 SH
40 DBV TECHNOLOGIES S A DBVT 23306J309 $2.6M 0.49% 156,906 SH
41 ANAVEX LIFE SCIENCES CORP Call AVXL 032797300 $1.4M 0.26% 521,300 SH
42 PROMIS NEUROSCIENCES INC PMN 74346M505 $1.1M 0.21% 86,150 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $529.1M 42 0001172661-26-003750
2026-03-31 2026-05-15 $435.1M 42 0001172661-26-002272
2025-12-31 2026-02-17 $308.4M 29 0001172661-26-001093
2025-09-30 2025-11-14 $242.5M 30 0001814554-25-000164
Filer Information
Address
165 MASON STREET, 3RD FLOOR
GREENWICH, CT 06830
Phone
(203) 971-3300
Filing Manager
GREAT POINT PARTNERS LLC
Greenwich, CT
Signatory
Dr. Jeffrey R. Jay, M.D.
Senior Managing Member